Engineered immune cells take on Hard-to-Treat prostate cancer

NCT ID NCT06236139

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study tests whether a new cell therapy called STEAP1 CAR T, given together with the hormone drug enzalutamide, is safe and effective for men with metastatic castration-resistant prostate cancer (mCRPC). The therapy uses a patient's own immune cells, modified in the lab to better target prostate cancer cells. The trial will enroll 48 participants and monitor side effects, tumor shrinkage, and PSA levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
STEAP1 CAR T-cells (a type of cell therapy) and enzalutamide (a hormone-blocking drug)
What this could lead to
If successful, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with only 48 participants, so results may not apply broadly. CAR T-cell therapy can cause serious side effects, and it is unknown if the combination will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.